We are seeking a scientist with a strong understanding of the fundamentals of pharmacology and experience in small molecule drug discovery to join our In Vivo Pharmacology group. In this role, you will serve as pharmacology subject matter expert on cross-functional project teams. You will independently design and execute in vivo studies to drive drug discovery projects for targeted protein degraders across a variety of diseases including oncology, inflammation, and immunity.

Kymera Therapeutics is a publicly listed, clinical stage biotechnology company pioneering the field of targeted protein degradation (TPD) to bring life-changing medicines to patients that need them. Kymera’s Pegasus™ TPD platform harnesses the body’s natural protein recycling machinery to degrade disease-causing proteins, with a focus on undrugged nodes in validated pathways currently inaccessible with conventional therapeutics. As we work toward becoming a fully-integrated biopharmaceutical company, we are growing and strengthening organizational capabilities and evolving our culture. As a result, Kymera has been recognized by both the Boston Globe and the Boston Business Journal as one of Boston’s top workplaces.

In 2023, we plan to continue to advance our leadership in TPD and enhance our capabilities to deliver on the potential of inventing a new class of protein degrader medicines for patients. Kymera is rapidly advancing four clinical stage programs in oncology and immunology, and is positioned to deliver one additional Investigational New Drug Applications (IND) annually. We are also actively advancing a broad pipeline of preclinical programs where TPD has the potential to provide a best-in-class approach, both internally and in collaboration with our partners Sanofi and Vertex Pharmaceuticals.

Responsibilities:

• Design and drive the execution of in vivo pharmacology strategies, both in-house and with external academic partners or CROs, to support Kymera’s discovery and development programs.
• Identify or develop novel disease models to drive proof of mechanism and proof of concept studies.
• Deploy and perform PK/PD/Efficacy studies in relevant disease models to define exposure response relationships and determine appropriate dosing regimens.
• Work effectively with other disciplines, including cell biology, DMPK, and safety/tox to collectively build the preclinical data package for clinical candidate nomination.
• Play an active role in expanding and growing internal pharmacology capabilities.
• Mentor and manage junior scientist(s).
• Participate in evaluation of novel targets and projects to continually refresh the drug discovery pipeline and progress the platform.
• Contribute to the preparation of regulatory submissions and publications.

Qualifications:

• Ph.D. or M.S. in cell biology, pharmacology, or related field of biomedical sciences with a minimum of 5-7 years of experience in a drug discovery setting.
• Proficiency and hands-on experience with acute and chronic in vivo models of oncology, inflammation, or autoimmunity.
• Proficiency with pharmacokinetic principles and in vivo methodologies to drive understanding of PK/PD/Efficacy relationships.
• Excellent project management skills and the ability to effectively manage CROs and to facilitate interactions with academic labs and companies to ensure project progression.
• Strong interpersonal, collaborative and communication skills.
• Previous experience in ubiquitin proteasome system is preferred.

Kymera Therapeutics is proud to be an equal opportunity employer, seeking to create a welcoming and diverse environment.  All applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, veteran status or any other applicable legally protected characteristics.